Abstract
Background Although COVID-19 infection has been associated with a number of clinical and environmental risk factors, host genetic variation has also been associated with the incidence and morbidity of infection. The CRP gene codes for a critical component of the innate immune system and CRP variants have been reported associated with infectious disease and vaccination outcomes. We investigated possible associations between COVID-19 outcome and a limited number of candidate gene variants including rs1205.
Methodology/Principal Findings The Strong Heart and Strong Heart Family studies have accumulated detailed genetic, cardiovascular risk and event data in geographically dispersed American Indian communities since 1988. Chi-square tests, logistic regression and generalized linear mixed models (implemented in SOLAR) were used in analysis. Genotypic data and 91 COVID-19 adjudicated deaths or hospitalizations from 2/1/20 through 3/1/23 were identified among 3,780 participants in two subsets. Among 21 candidate variants including genes in the interferon response pathway, APOE, TMPRSS2, TLR3, the HLA complex and the ABO blood group, only rs1205, a 3’ untranslated region variant in the CRP gene, showed nominally significant association in T-dominant model analyses (odds ratio 1.859, 95%CI 1.001-3.453, p=0.049) after adjustment for age, sex, center, body mass index, and a history of cardiovascular disease. Within the younger subset, association with the rs1205 T-Dom genotype was stronger, both in the same adjusted logistic model and in the SOLAR analysis also adjusting for other genetic relatedness.
Conclusion A T-dominant genotype of rs1205 in the CRP gene is associated with COVID-19 death or hospitalization, even after adjustment for relevant clinical factors and potential participant relatedness. Additional study of other populations and genetic variants of this gene are warranted.
Author summary Considerable inter-individual variability in COVID-19 clinical outcome has been noted from the onset of this pandemic. Some risk factors, such as age, diabetes, obesity, prior cardiovascular disease (CVD) are well established. The possibility of inherited, host genetic risk factors has also been examined and a number validated in very large, population based datasets. The present study leveraged on-going clinical surveillance of CVD and available genetic information in an American Indian population to investigate potential host genetic contributors to COVID-19 morbidity and mortality. Although the number of cases ascertained was relatively small, a novel variant in the C-reactive protein gene was found to be associated with COVID-19 outcome. This protein constitutes a critical component of the innate immune system and CRP variants have been reported associated with infectious disease and vaccination outcomes. Improved understanding of the pathophysiology of this infection may allow more targeted therapy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by NIHLBI contract: 75N92019D00029 NIMHD: R01-MD012765 NIDDK: R01-DK117445 NIEHS: R21ES033119 NIEHS: R01ES021367 NIEHS: P42ES033719
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Arizona Area Indian Health Service gave ethical approval for this work IRB of MedStar Health Research Institute gave ethical approval for this work IRB of Great Plains Area Indian Health Service gave ethical approval for this work IRB of Oglala Sioux Tribe Research Review Board gave ethical approval for this work IRB of University of Oklahoma Health Sciences gave ethical approval for this work IRB of Oklahoma Area Indian Health Service gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data underlying the results of this study are owned and controlled by the Tribal entities that approved its collection. This fact is clearly stated in the Tribal resolutions authorizing the research; and it must be recognized that these Tribal communities are an independent, sovereign governments, in control over research activities within their borders. Access to data and materials can be accomplished by application to Mr. Guthrie Ducheneaux, IT director, Missouri Breaks Research Inc, 505 S Willow St, Eagle Butte, SD 57625, 605-964-3419, email: guthrie.ducheneaux{at}mbiri.com, who will arrange for further consultation with the appropriate Tribal partners. Approximately 2 to 3 months may be required. The authors received special access privileges to the data due to their relationship with the Tribal Governments, however, interested researchers who apply for data access will be able to access the same data as the authors.
